stockrow
Monday 9 November 2026
Export INO’s income statement to Excel — free account
Inovio Pharmaceuticals, Inc.
INOInovio Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65,300.00, down 70.0% from fiscal 2024.
- Revenue
- −83.2%
- EPS
- +88.5%
- Free cash flow
- +13.4%
Quarter to June 2026, against a year earlier
1.22
0.23
−15.86%
Follow INO
Alert me
Inovio Pharmaceuticals, Inc. (INO) P/E ratio
Inovio Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2025 | 0.0× | — |
| Dec 2024 | 0.0× | — |
| Jun 2024 | 0.0× | — |
| Dec 2023 | 0.0× | — |
| 35 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NGEN NervGen Pharma Corp. compare | n/m |
| MGNX MacroGenics, Inc. compare | n/m |
| ANTX AN2 Therapeutics, Inc. compare | n/m |
| ALXO ALX Oncology Holdings Inc. compare | n/m |
| IPHA Innate Pharma S.A. Sponsored ADR compare | n/m |
| SION Sionna Therapeutics, Inc. compare | n/m |
| CNTN Canton Strategic Holdings, Inc. compare | n/m |
| STRO Sutro Biopharma, Inc. compare | n/m |
| INO Inovio Pharmaceuticals, Inc. | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)